Get started
Author

Gérard Flesch

Observed names: G Flesch, G. Flesch, Gerard Flesch
OpenAlex ID: A5018533252
Oxcarbazepine Placebo‐Controlled, Dose‐Ranging Trial in Refractory Partial Epilepsy
2000 · G Barcs, E B Walker, et al. · Epilepsia · 225
Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man
1997 · G. Flesch, P. Müller, et al. · European Journal of Clinical Pharmacology · 203
Clinical Pharmacology and Pharmacokinetics of Oxcarbazepine
1994 · P. Lloyd, G. Flesch, et al. · Epilepsia · 145
Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose
1997 · F. Waldmeier, G. Flesch, et al. · Xenobiotica · 133
Pharmacokinetics of valsartan in patients with liver disease
1997 · Laurence J. Brookman, Paul E. Rolan, et al. · Clinical Pharmacology & Therapeutics · 95
Iron chelation with desferrioxamine B in adults with asymptomatic Plasmodium falciparum parasitemia [see comments]
1992 · VR Gordeuk, PE Thuma, et al. · Blood · 91
Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects
1997 · P. M�ller, G. Flesch, et al. · European Journal of Clinical Pharmacology · 70
Pharmacokinetics of Pamidronate in Patients With Bone Metastases
1992 · S. Leyvraz, U. Hess, et al. · JNCI Journal of the National Cancer Institute · 67
PDF
Determination of the bisphosphonate pamidronate disodium in urine by pre-column derivatization with fluorescamine, high-performance liquid chromatography and fluorescence detection
1989 · G. Flesch, S.A. Hauffe · Journal of Chromatography B Biomedical Sciences and Applications · 59
Intravenous Pamidronate for Treatment of Reflex Sympathetic Dystrophy During Breast Feeding
2000 · K. Siminoski, A. A. Fitzgerald, et al. · Journal of Bone and Mineral Research · 47
Pharmacokinetic evaluation of pamidronate after oral administration: A study on dose proportionality, absolute bioavailability, and effect of repeated administration
1993 · L. Hyldstrup, G. Flesch, et al. · Calcified Tissue International · 46
Determination of the R-(−) and S-(+) enantiomers of the monohydroxylated metabolite of oxcarbazepine in human plasma by enantioselective high-performance liquid chromatography
1992 · G. Flesch, E. Francotte, et al. · Journal of Chromatography B Biomedical Sciences and Applications · 46
Pharmacokinetics of the Monohydroxy Derivative of Oxcarbazepine and Its Enantiomers after a Single Intravenous Dose Given as Racemate Compared with a Single Oral Dose of Oxcarbazepine
2011 · G Flesch, C Czendlik, et al. · Drug Metabolism and Disposition · 44
Effects of dextropropoxyphene on the steady-state kinetics of oxcarbazepine and its metabolites
2009 · P. H. Mogensen, L. Jórgensen, et al. · Acta Neurologica Scandinavica · 39
An interaction study with cimetidine and the new angiotensin II antagonist valsartan
1998 · E. K. Schmidt, K.-H. Antonin, et al. · European Journal of Clinical Pharmacology · 39
Improved determination of the bisphosphonate pamidronate disodium in plasma and urine by pre-column derivatization with fluorescamine, high-performance liquid chromatography and fluorescence detection
1991 · G. Flesch, N. Tominaga, et al. · Journal of Chromatography B Biomedical Sciences and Applications · 35
The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers
1994 · P. H. Degen, G. Flesch, et al. · Biopharmaceutics & Drug Disposition · 32
Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide
1997 · M. Bindschedler, P. Degen, et al. · European Journal of Clinical Pharmacology · 31
Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state
1995 · J.‐M. Cardot, P. Degen, et al. · Biopharmaceutics & Drug Disposition · 24
Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension
2015 · Didier Renard, Thomas Bouillon, et al. · British Journal of Clinical Pharmacology · 20
Assessment of the bioequivalence of two oxcarbazepine oral suspensions versus a film-coated tablet in healthy subjects
2003 · G. Flesch, D. Tudor, et al. · International Journal of Clinical Pharmacology and Therapeutics · 15
Replacing Carbamazepine Slow-Release Tablets With Carbamazepine Suppositories: A Pharmacokinetic and Clinical Study in Children With Epilepsy
1995 · Jan Arvidsson, Heimo L. Nilsson, et al. · Journal of Child Neurology · 14
Urinary Excretion of Aminohydroxypropylidene Bisphosphonate in Cancer Patients after Single Intravenous Infusions
1993 · Elliot Redalieu, Jean M. Coleman, et al. · Journal of Pharmaceutical Sciences · 11
Oxcarbazepine final market image tablet formulation bioequivalence study after single administration and at steady state in healthy subjects
2002 · G. Flesch, D. Tudor, et al. · International Journal of Clinical Pharmacology and Therapeutics · 10
Quantitative determination of CGP 61755, a protease inhibitor, in plasma and urine by high-performance liquid chromatography and fluorescence detection
1997 · G Flesch, Ch Mann, et al. · Journal of Chromatography B Biomedical Sciences and Applications · 5
Works count: 67
Citation count: 1,554
H-index: 20
I10-index: 24
Year
Topic
Type